Timothy Carll

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein et al. · Journal of Clinical Oncology · 2021 · 220 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)

Jason J. Luke, Daniel J. Olson, Jacob B. Allred et al. · Clinical Cancer Research · 2019 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.

Daniel J. Olson, Jason J. Luke, Andrew Poklepovic et al. · Journal of Clinical Oncology · 2020 · 25 citations

Medicine, Oncology, Pharmacotherapy +17

Refractory vaccine‐induced immune thrombotic thrombocytopenia (<scp>VITT</scp>) managed with delayed therapeutic plasma exchange (<scp>TPE</scp>)

Ajay Major, Timothy Carll, Clarence W. Chan et al. · Journal of Clinical Apheresis · 2021 · 22 citations

Life Sciences, Hematology, Immunology +17

Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).

Daniel J. Olson, Jason J. Luke, Sigrun Hallmeyer et al. · Journal of Clinical Oncology · 2018 · 20 citations

Pharmacy, Oncology, Pharmacotherapy +17